 | |
ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado.
The Company’s lead investigational product is Gencaro™ (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic... More >> |
|
| Date | Title | | | 01/20/10 | ARCA Announces Publication of Bucindolol Data in Circulation: Heart Failure| Data from the Clinical Study BEST Indicate That in the Study Norepinephrine Lowering and Clinical Therapeutic Responses to Bucindolol Were Strongly Influenced by alpha-2C-Adrenergic Receptor GenotypeData Suggest Potential Use of Genetic Biomarkers to Define Which Patients Are Most Likely to Respond to the Pharmacologically Unique Beta-Blocker BucindololBROOMFIELD, Colo., Jan 20, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing geneticall... |
|  | | 01/11/10 | ARCA biopharma Receives Notice of Allowance for Patent for Treating Heart Failure Patients with Bucindolol Based on Genetic Testing| BROOMFIELD, Colo., Jan 11, 2010 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically targeted therapies for heart failure and other
cardiovascular diseases, today announced that it has received a Notice
of Allowance from the U.S. Patent and Trademark Office (USPTO) for its
U.S. Patent Application Number 11/226,908 entitled "Methods for
Treatment with Bucindolol Based on Genetic Targeting." The Notice of... |
| | | 12/22/09 | ARCA Announces Submission of a Request for Special Protocol Assessment for Gencarotm Development in Genotype-Defined Heart Failure Population| BROOMFIELD, Colo., Dec 22, 2009 (BUSINESS WIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigation... |
| | | 11/23/09 | ARCA Receives FDA Fast Track Designation for GencaroTM Development in Genotype-Defined Heart Failure Population| BROOMFIELD, Colo.--(BUSINESS WIRE)--Nov. 23, 2009--
ARCA biopharma, Inc. (Nasdaq:ABIO) today announced that the U.S. Food
and Drug Administration (FDA) has designated as a Fast Track development
program the investigation of GencaroTM, the Company’s
investigational, pharmacologically unique beta-blocker and mild
vasodilator, for the reduction of cardiovascular mortality and
cardiovascular hospitalizations in a genotype-defined heart failure
pop... |
| |
|
|
| There are currently no events scheduled. |
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever ARCA biopharma, Inc. posts new information to the site. Just enter your e-mail address and click Submit. |
| | | |
